Robeco Institutional Asset Management B.V. increased its position in shares of Abbott Laboratories (NYSE:ABT) by 24.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 131,413 shares of the healthcare product maker’s stock after acquiring an additional 26,148 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Abbott Laboratories were worth $7,500,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Rowland & Co. Investment Counsel ADV acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $102,000. Heritage Trust Co boosted its position in Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares in the last quarter. Tributary Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter valued at $106,000. Thompson Davis & CO. Inc. raised its stake in shares of Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares during the last quarter. Finally, Cerebellum GP LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $133,000. Institutional investors and hedge funds own 70.01% of the company’s stock.
In other Abbott Laboratories news, Chairman Miles D. White sold 276,886 shares of Abbott Laboratories stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the sale, the chairman now directly owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Stephen R. Fussell sold 13,313 shares of Abbott Laboratories stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $62.84, for a total transaction of $836,588.92. Following the completion of the sale, the executive vice president now directly owns 152,343 shares of the company’s stock, valued at $9,573,234.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 405,137 shares of company stock valued at $22,686,356. Insiders own 0.76% of the company’s stock.
Abbott Laboratories (NYSE ABT) opened at $59.71 on Friday. Abbott Laboratories has a 52 week low of $42.31 and a 52 week high of $64.60. The firm has a market cap of $103,930.00, a price-to-earnings ratio of 57.41, a P/E/G ratio of 1.77 and a beta of 1.55. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.26 and a current ratio of 2.26.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.88%. The business had revenue of $7.59 billion during the quarter, compared to the consensus estimate of $7.38 billion. During the same quarter last year, the firm earned $0.65 earnings per share. Abbott Laboratories’s quarterly revenue was up 42.3% on a year-over-year basis. analysts expect that Abbott Laboratories will post 2.86 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be paid a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 1.88%. The ex-dividend date of this dividend is Thursday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 107.69%.
Several equities analysts have recently issued reports on the stock. Barclays raised their price target on shares of Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target on shares of Abbott Laboratories in a research note on Thursday, January 25th. Royal Bank of Canada reaffirmed a “buy” rating and set a $67.00 price target on shares of Abbott Laboratories in a research note on Thursday, January 25th. Leerink Swann reaffirmed a “market perform” rating and set a $68.00 price target (up previously from $60.00) on shares of Abbott Laboratories in a research note on Thursday, January 25th. Finally, Citigroup raised their price target on shares of Abbott Laboratories from $59.00 to $64.00 and gave the company a “neutral” rating in a research note on Tuesday, January 30th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Abbott Laboratories presently has an average rating of “Buy” and a consensus target price of $65.47.
COPYRIGHT VIOLATION NOTICE: “Robeco Institutional Asset Management B.V. Has $7.50 Million Position in Abbott Laboratories (ABT)” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/24/robeco-institutional-asset-management-b-v-has-7-50-million-position-in-abbott-laboratories-abt.html.
Abbott Laboratories Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.